Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

The FDA has removed the REMS program requirement for currently approved BCMA- and CD19-directed autologous CAR T-cell therapies.

Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.

The ACIP has recommended that patients only receive seasonal influenza vaccines that do not contain thimerosal.